DihydromethysticinCAS# 19902-91-1 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 19902-91-1 | SDF | Download SDF |
PubChem ID | 229852 | Appearance | Cryst. |
Formula | C15H16O5 | M.Wt | 276.28 |
Type of Compound | Phenols | Storage | Desiccate at -20°C |
Solubility | Freely soluble in dioxane and methanol; slightly soluble in water | ||
Chemical Name | 2-[2-(1,3-benzodioxol-5-yl)ethyl]-4-methoxy-2,3-dihydropyran-6-one | ||
SMILES | COC1=CC(=O)OC(C1)CCC2=CC3=C(C=C2)OCO3 | ||
Standard InChIKey | RSIWXFIBHXYNFM-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C15H16O5/c1-17-12-7-11(20-15(16)8-12)4-2-10-3-5-13-14(6-10)19-9-18-13/h3,5-6,8,11H,2,4,7,9H2,1H3 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | 1. The induction of CYP3A23 by dihydromethysticin and desmethoxyyangonin involves transcription activation, probably through a pregnane X receptor (PXR).-independent or PXR-involved indirect mechanism. 2. Dihydromethysticin non-competitively inhibits the specific binding of [3H]-batrachotoxinin-A 20-alpha-benzoate to receptor site 2 of voltage-gated Na+ channels. |
Targets | Sodium Channel | P450 (e.g. CYP17) |
Dihydromethysticin Dilution Calculator
Dihydromethysticin Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.6195 mL | 18.0976 mL | 36.1952 mL | 72.3903 mL | 90.4879 mL |
5 mM | 0.7239 mL | 3.6195 mL | 7.239 mL | 14.4781 mL | 18.0976 mL |
10 mM | 0.362 mL | 1.8098 mL | 3.6195 mL | 7.239 mL | 9.0488 mL |
50 mM | 0.0724 mL | 0.362 mL | 0.7239 mL | 1.4478 mL | 1.8098 mL |
100 mM | 0.0362 mL | 0.181 mL | 0.362 mL | 0.7239 mL | 0.9049 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Syringaresinol diacetate
Catalog No.:BCN4874
CAS No.:1990-77-8
- Kaempferol 3-O-beta-sophoroside
Catalog No.:BCN3336
CAS No.:19895-95-5
- 29-Nor-20-oxolupeol
Catalog No.:BCN6678
CAS No.:19891-85-1
- Jaborosalactone D
Catalog No.:BCN7946
CAS No.:19891-82-8
- Nagilactone B
Catalog No.:BCN4049
CAS No.:19891-51-1
- Atazanavir
Catalog No.:BCC3622
CAS No.:198904-31-3
- Continentalic acid
Catalog No.:BCN6526
CAS No.:19889-23-7
- Humulene epoxide II
Catalog No.:BCN4873
CAS No.:19888-34-7
- Alisol A
Catalog No.:BCN3455
CAS No.:19885-10-0
- H-Phe(2-F)-OH
Catalog No.:BCC3222
CAS No.:19883-78-4
- H-D-Phg-OMe.HCl
Catalog No.:BCC3314
CAS No.:19883-41-1
- Z-D-Tyr(tBu)-OH.DCHA
Catalog No.:BCC2744
CAS No.:198828-72-7
- Bakkenolide A
Catalog No.:BCN5402
CAS No.:19906-72-0
- Maackiain
Catalog No.:BCN1236
CAS No.:19908-48-6
- H-Phe(4-Me)-OH
Catalog No.:BCC3270
CAS No.:1991-87-3
- Balaglitazone
Catalog No.:BCC1395
CAS No.:199113-98-9
- T 98475
Catalog No.:BCC7395
CAS No.:199119-18-1
- Furanodiene
Catalog No.:BCN6454
CAS No.:19912-61-9
- Chamigrenal
Catalog No.:BCN7847
CAS No.:19912-84-6
- Futoenone
Catalog No.:BCN6408
CAS No.:19913-01-0
- Enniatin B1
Catalog No.:BCN4853
CAS No.:19914-20-6
- Boc-D-N-Me-Ala-OH
Catalog No.:BCC3211
CAS No.:19914-38-6
- O6-Benzylguanine
Catalog No.:BCC6485
CAS No.:19916-73-5
- Dehydroglyasperin C
Catalog No.:BCN6790
CAS No.:199331-35-6
Desmethoxyyangonin and dihydromethysticin are two major pharmacological kavalactones with marked activity on the induction of CYP3A23.[Pubmed:15282211]
Drug Metab Dispos. 2004 Nov;32(11):1317-24.
Kava kava (Piper methysticum), an herbal remedy, is widely used for the treatment of mild to moderate cases of anxiety. The therapeutic activity is presumably achieved through multiple constituents called kavalactones. Recently, kava extracts were shown to induce CYP3A4 and activate human pregnane X receptor (PXR). This study was undertaken to test the ability of purified kavalactones to induce CYP3A23 and activate PXR. Rat hepatocytes were treated with desmethoxyyangonin, dihydrokawain, Dihydromethysticin, kawain, methysticin, or yangonin, and the expression of CYP3A23 was monitored. Among the kavalactones, only desmethoxyyangonin and Dihydromethysticin markedly induced the expression of CYP3A23 (approximately 7-fold). A similar magnitude of induction was detected with combined six kavalactones at a noninductive concentration when individually used. The induced expression, however, was markedly reduced or completely abolished if Dihydromethysticin, desmethoxyyangonin, or both were excluded from the mixtures. Interestingly, regardless of whether Dihydromethysticin or desmethoxyyangonin was used alone or together with other kavalactones, similar amounts of total kavalactones were needed to produce comparable induction, suggesting that the inductive activity of Dihydromethysticin and desmethoxyyangonin is additively/synergistically enhanced by other kavalactones. In addition, treatment with Dihydromethysticin, desmethoxyyangonin, or pregnenolone 16alpha-carbonitrile (PCN) markedly increased the levels of CYP3A23 mRNA, and inhibition of mRNA synthesis abolished the induction. In contrast to PCN, Dihydromethysticin and desmethoxyyangonin only slightly activated rat or human PXR. These findings suggest that the induction of CYP3A23 by Dihydromethysticin and desmethoxyyangonin involves transcription activation, probably through a PXR-independent or PXR-involved indirect mechanism.
Kavain, dihydrokavain, and dihydromethysticin non-competitively inhibit the specific binding of [3H]-batrachotoxinin-A 20-alpha-benzoate to receptor site 2 of voltage-gated Na+ channels.[Pubmed:9690349]
Planta Med. 1998 Jun;64(5):458-9.
The mode of action of the kava pyrones, kavain, dihydrokavain and Dihydromethysticin on the specific binding of [3H]-batrachotoxinin-A 20-alpha-benzoate to epitope 2 of voltage-dependent Na+ channels was investigated by performing saturation experiments in the presence and absence of these kava pyrones. The tested compounds significantly decreased the apparent total number of binding sites (Bmax) for [3H]-batrachotoxinin-A 20-alpha-benzoate (control: 0.5 pmol/mg protein, kava pyrones: 0.2-0.27 pmol/mg protein) with little change in the equilibrium constants (KD) for [3H]-batrachotoxin-A 20-alpha-benzoate (control: 28.2 nM, kava pyrones: 24-31 nM). The results indicate for the kava pyrones a non-competitive inhibition of the specific [3H]-batrachotoxinin-A 20-alpha-benzoate binding to receptor site 2 of voltage-gated Na+ channels.